[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
2. Tantawy AA, El-Bostany EA, Adly AA, Abou El Asrar M, El-Ghouroury EA, Abdulghaffar EE: Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis; 2010 Jan;21(1):28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR).
  • The present study aimed to assess the prevalence of MTHFR polymorphisms C677>T and A1298>C in Egyptian children with ALL and the relation to the frequency of drug-induced complications and relapse rate.
  • The severity and duration of hepatic, mucosal and infectious complications during therapy were reported.
  • Methotrexate therapy was significantly associated with increased grade III/IV toxicity in TT genotype: diarrhea in 81.3%, oral mucositis in 81.3%, elevated transaminases in 87.5%, neutropenia in 78.7% compared to values of 7.7, 7.7, 15.3, and 7.7% in CC genotype, respectively (P < 0.0001, P < 0.0001, P < 0.0001, and P = 0.03).
  • MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Alleles. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Drug-Induced Liver Injury / etiology. Drug-Induced Liver Injury / genetics. Egypt / epidemiology. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Polymorphism, Restriction Fragment Length. Prednisone / administration & dosage. Recurrence. Stomatitis / chemically induced. Stomatitis / genetics. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood Coagul Fibrinolysis. 2010 Mar;21(2):200
  • (PMID = 19923983.001).
  • [ISSN] 1473-5733
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


3. Tokimasa S, Ohta H, Sawada A, Matsuda Y, Kim JY, Nishiguchi S, Hara J, Takihara Y: Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Exp Hematol; 2001 Jan;29(1):93-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because homozygous rae28-deficient (rae28-/-) mice died in the perinatal period, we examined lymphocyte development by generating chimeric mice reconstituted with green fluorescence protein-labeled mutant fetal liver cells as well as in in vitro culture systems.
  • Furthermore, the human RAE28 locus may provide a candidate gene causing the molecular pathogenesis of childhood B-cell precursor ALL.
  • [MeSH-major] B-Lymphocytes / cytology. Carrier Proteins. Hematopoiesis / genetics. Homeodomain Proteins / genetics. Immunologic Deficiency Syndromes / genetics. Neoplasm Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Animals. Burkitt Lymphoma / pathology. Cell Differentiation / genetics. Cell Transplantation. Child. Child, Preschool. Chimera. Chromosomes, Human, Pair 12 / genetics. Coculture Techniques. Crosses, Genetic. Female. Gene Deletion. Gene Expression Regulation, Leukemic. Genes, Reporter. Genotype. Green Fluorescent Proteins. Hematopoietic Stem Cells / drug effects. Humans. Interleukin-7 / pharmacology. Liver / cytology. Liver / embryology. Luminescent Proteins / genetics. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Polycomb Repressive Complex 1. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Recombinant Fusion Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes / cytology. Thymus Gland / abnormalities. Thymus Gland / embryology. Tumor Cells, Cultured / drug effects

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11164110.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Homeodomain Proteins; 0 / Interleukin-7; 0 / Luminescent Proteins; 0 / Neoplasm Proteins; 0 / PHC1 protein, human; 0 / Phc1 protein, mouse; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


Advertisement
4. Dzieran J, Beck JF, Sonnemann J: Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci; 2008 Aug;99(8):1685-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver cancer, however, is largely resistant to TRAIL and, thus, requires sensitization for TRAIL-mediated cytotoxicity.
  • Sensitization may be achieved by cotreatment with chemotherapeutic agents.
  • In this study, we comparatively investigated the treatment efficacy of TRAIL in combination with histone deacetylase inhibitors (HDI) versus TRAIL in combination with conventional cytostatics in the hepatocellular carcinoma cell line HepG2 and in the childhood hepatoblastoma cell line Huh6.
  • In conclusion, our data suggest that HDI are potent sensitizers to TRAIL in hepatoma cells and that the combination of HDI and TRAIL is selectively active in hepatoma cells without affecting normal hepatocytes, indicating that the combination of HDI and TRAIL may be an effective approach for the treatment of advanced liver cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols. Apoptosis / drug effects. Histone Deacetylases / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / drug therapy. Cell Line, Tumor. Drug Resistance, Neoplasm. Hepatoblastoma / drug therapy. Hepatocytes / drug effects. Histone Deacetylase Inhibitors. Humans. Liver Neoplasms / drug therapy. Rats

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754884.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


5. Liu Y, Li PK, Li C, Lin J: Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem; 2010 Aug 27;285(35):27429-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.
  • Recent studies demonstrate that high levels of IL-6 are associated with hepatocellular carcinoma, the most common type of liver cancer.
  • Here we reported that IL-6 promoted survival of human liver cancer cells through activating STAT3 in response to doxorubicin treatment.
  • To elucidate the mechanism of the anti-apoptotic function of IL-6, we investigated if STAT3 mediated this drug resistance.
  • Therefore, our results demonstrated that targeting STAT3 signaling could interrupt the anti-apoptotic function of IL-6 in human liver cancer cells.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2007 Dec;117(12):3988-4002 [18060036.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3846-56 [18060032.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):353-8 [17962206.001]
  • [Cites] J Neurooncol. 2009 Jan;91(2):165-74 [18839277.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):79-80 [19185839.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):91-102 [19185844.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):103-13 [19185845.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):114-23 [19185846.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):155-69 [19011039.001]
  • [Cites] J Neurosurg. 2009 Aug;111(2):219-25 [19326989.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):798-809 [19851315.001]
  • [Cites] Eur J Haematol. 2010 Feb 1;84(2):137-44 [19878271.001]
  • [Cites] Cell. 2010 Jan 22;140(2):197-208 [20141834.001]
  • [Cites] Endocr Relat Cancer. 2010 Mar;17(1):241-53 [19966016.001]
  • [Cites] Prostate. 2000 Feb 1;42(2):88-98 [10617865.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):186-95 [10639189.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):239-42 [10639195.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):47-53 [11391686.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1947-53 [11751424.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 22;292(1):287-91 [11890706.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3949-60 [12037677.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):319-29 [12545153.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1517-27 [12629515.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3863-71 [14500688.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):978-80 [14523032.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5426-34 [15184887.001]
  • [Cites] Nature. 1988 Mar 3;332(6159):83-5 [3258060.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 [9716487.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2269-76 [15781640.001]
  • [Cites] Neoplasia. 2010 Jan;12(1):39-50 [20072652.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):497-505 [15838876.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5552-60 [16007214.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6333-41 [16144938.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):11-9 [16397018.001]
  • [Cites] Hepatology. 2006 Mar;43(3):474-84 [16496306.001]
  • [Cites] J Hepatol. 2006 Jun;44(6):1055-65 [16469407.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):41-51 [17186030.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):112-21 [17237271.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):267-72 [17352242.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2822-32 [17072336.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3660-3 [18060028.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):7-9 [18167335.001]
  • (PMID = 20562100.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA133652; United States / NCI NIH HHS / CA / R21CA133652-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Antibiotics, Antineoplastic; 0 / Antibodies; 0 / IL6 protein, human; 0 / Interleukin-6; 0 / LLL12 compound; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Sulfonamides; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2930741
  •  go-up   go-down


6. McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W: Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg; 2003 Mar;38(3):308-14; discussion 308-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatoblastoma is the most common primary hepatic malignancy of childhood, frequently presenting as advanced disease.
  • At week 6, 10 control/treated mice were killed and remaining animals maintained without treatment until week 8.
  • Anti-VEGF agents may represent new therapeutic alternatives for children with advanced disease.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Endothelial Growth Factors / antagonists & inhibitors. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy. Lymphokines / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Animals. Antibody Specificity. Female. Humans. Intercellular Signaling Peptides and Proteins / immunology. Mice. Mice, Nude. Neoplasm Transplantation. Peritoneal Neoplasms / secondary. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12632340.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


7. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Six had stage IV characteristics, whereas another 9 patients had stage III disease.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • Preliminary results of our study suggest that H. pylori may not be the responsible agent for NHL involved the abdomen in childhood.
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


8. Benjamin R, Helman L, Meyers P, Reaman G: A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther; 2001 Aug 10;12(12):1591-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcomas are malignant tumors arising from skeletal tissue and occur most frequently during childhood and adolescence.
  • Because adenovirus is quickly cleared by normal tissues, especially the liver, systemic administration has been problematic.
  • Although bioavailability would be decreased following exposure to the liver, the OcaP1 construct should not be hepatotoxic due to OC-restricted tissue expression of the Ela protein.
  • Metastatic disease to the lung is a major problem and often is the cause of death for patients with osteogenic sarcoma.
  • [MeSH-minor] Cell Line. Culture Media, Serum-Free / pharmacology. Dose-Response Relationship, Drug. Genetic Therapy / adverse effects. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lung Neoplasms / therapy. Maximum Tolerated Dose. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11529247.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free
  •  go-up   go-down


9. Perilongo G, Brown J, Shafford E, Brock P, De Camargo B, Keeling JW, Vos A, Philips A, Pritchard J, Plaschkes J: Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer; 2000 Oct 15;89(8):1845-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors.
  • In light of the overall improvement in the survival of HB patients since the introduction of cisplatin (CDDP) in the therapeutic armament of this tumor, the question has been raised whether patients with metastatic HB also would benefit from this drug.
  • The purpose of the current study was to address this issue by analyzing the treatment outcome of those patients presenting with metastases who entered into the first HB study on childhood liver tumors conducted by the International Society of Paediatric Oncology (SIOPEL 1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatoblastoma / drug therapy. Hepatoblastoma / secondary. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Adolescent. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11042582.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Attarbaschi A, Mann G, Dworzak M, Urban C, Fink FM, Dieckmann K, Riehm H, Gadner H, Austrian Cooperative Study Group: Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. Wien Klin Wochenschr; 2002 Feb 28;114(4):148-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
  • In the trials BFM-A (Austria) 81 and ALL A 84, treatment stratification was performed using a risk factor, which was calculated from the initial peripheral blast cell count, and size of liver and spleen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Austria. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Multicenter Studies as Topic. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Prognosis. Retrospective Studies. Risk


12. Rutgers M, Buitenhuis CK, van der Valk MA, Hoefnagel CA, Voûte PA, Smets LA: [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Int J Cancer; 2000 Dec 20;90(6):312-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [(131)I]Metaiodobenzylguanidine ([(131)I]MIBG) targeted radiotherapy is effective in debulking childhood neuroblastoma.
  • Groups of 4-9 animals were treated with 10-100 MBq radioiodinated MIBG.
  • For the neuroblastoma, we induced focal intrahepatic microscopic tumors by intrasplenic injection and evaluated total liver weights 26 days after therapy.
  • In conclusion, [(131)I]MIBG is decreasingly effective in microscopic disease and can therefore not be curative as a single agent.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Adrenal Gland Neoplasms / radiotherapy. Antineoplastic Agents / therapeutic use. Iodine Radioisotopes / therapeutic use. Neuroblastoma / radiotherapy. Pheochromocytoma / radiotherapy. Radiopharmaceuticals / therapeutic use
  • [MeSH-minor] Animals. Female. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. PC12 Cells. Rats. Transplantation, Heterologous


13. Wang HS, Gao YJ, Li J, Lu FJ, Miao H, Qian XW, Zhu XF: [Clinical characteristics of hepatic veno-occlusive disease in 6 children with hematologic neoplasm treated with 6-thioguanine]. Zhonghua Er Ke Za Zhi; 2010 Sep;48(9):708-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of hepatic veno-occlusive disease in 6 children with hematologic neoplasm treated with 6-thioguanine].
  • OBJECTIVE: To improve the treatment of drug related childhood hepatic veno-occlusive disease (HVOD), clinical characteristics of 6 children with hematologic neoplasm from 2 hospitals of China Children's Leukemia Group (CCLG) treated with 6-thioguanine (6-TG) complicated with HVOD were analyzed.
  • METHOD: All the drug related HVOD patients were treated with CCLG acute lymphoblastic leukemia (ALL)-2008 protocol.
  • Most of 6 HVOD patients presented with pain in liver area, hepatomegaly on imaging, elevated aminotransferase and bilirubin (often ≥ 35 µmol/L), hydroperitonia was common, one with pleural fluid, illegible hepatic veins.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hepatic Veno-Occlusive Disease / drug therapy. Thioguanine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092535.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


14. Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, Kohl V, Adamson PC, Ayello J, vande Ven C, Perkins SL, Cairo MS, Children's Oncology Group: A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Clin Cancer Res; 2007 Sep 15;13(18 Pt 2):5652s-5660s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A radiolabeled anti-CD20 antibody, 90yttrium-ibritumomab-tiuxetan (90Y-IT), is Food and Drug Administration approved for adults with recurrent indolent CD20+ B cell-non-Hodgkin's lymphoma.
  • There is no data on the safety and feasibility of 90Y-IT in refractory childhood CD20+ lymphoma.
  • The following are the means of organ radiation exposure (cGy): kidneys 341 (112-515), liver 345 (83-798), lungs 309 (155-519), marrow 46 (20-78), spleen 565 (161-816), and total body 42 (14-68).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / immunology. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875803.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunoconjugates; 0 / Indium Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Turner PC, Sylla A, Kuang SY, Marchant CL, Diallo MS, Hall AJ, Groopman JD, Wild CP: Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):2053-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with hepatitis viruses and chronic exposure to high levels of dietary aflatoxins are the major etiologic agents for hepatocellular carcinoma in west Africa.
  • A challenge for the prevention of hepatocellular carcinoma in this region is that both hepatitis B virus and aflatoxin exposures start early in life; indeed, aflatoxin exposures can start in utero and continue unabated throughout childhood.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Aflatoxins / adverse effects. DNA, Neoplasm / blood. Genes, p53 / genetics. Liver Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103461.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES06052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aflatoxins; 0 / DNA, Neoplasm
  •  go-up   go-down


16. Engler S, Thiel C, Förster K, David K, Bredehorst R, Juhl H: A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies. Cancer Res; 2001 Apr 1;61(7):2968-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma (NB), the most common extracranial solid tumor in childhood is associated with poor prognosis in patients with advanced tumor stages.
  • Intra-aortal injection of human NB cells in nude rats resulted in the development of large invasive adrenal gland tumors and micrometastases in the liver and bones.
  • This study strongly suggests human anti-NB IgM antibodies as new agents for the therapy of neuroblastoma.
  • [MeSH-minor] Adrenal Gland Neoplasms / immunology. Animals. Apoptosis / immunology. Cell Division / immunology. Complement Activation / immunology. Cytotoxicity, Immunologic / immunology. Disease Models, Animal. Humans. Male. Neoplasm Metastasis. Rats. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11306475.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down






Advertisement